Jiangsu Hengrui Pharmaceuticals (600276.SH) subsidiary has obtained the drug clinical trial approval notice.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Suzhou Hengdiya Biopharmaceutical Co., Ltd. and Shanghai Hengdi Pharmaceutical Co., Ltd. have received the approval notice for clinical trials of injectable SHR-A2009 and Adebali monoclonal antibody injection from the National Medical Products Administration. Clinical trials will be conducted in the near future. According to the Drug Administration Law of the People's Republic of China and relevant regulations, upon review, the injectable SHR-A2009 and Adebali monoclonal antibody injection accepted on May 13, 2026, meet the relevant requirements for drug registration. Approval has been granted to conduct a Phase II clinical trial of injectable SHR-A2009 in combination with Adebali monoclonal antibody or in combination with third-generation EGFRTKI in patients with non-small cell lung cancer.